Cancer, Advanced Clinical Trial
Official title:
A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients
Part 1 of the study will assess the pharmacokinetics, safety, and tolerability of ridaforolimus (MK-8669) after administration of single and multiple 40 mg doses in Chinese participants with advanced cancer. Part 2 of the study is optional; participants can continue to receive the study treatment in a weekly regimen of daily oral doses of ridaforolimus 40 mg for five consecutive days followed by two days off-treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04604873 -
The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)
|
N/A | |
| Completed |
NCT00750178 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
|
Phase 1 | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Recruiting |
NCT05200572 -
Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers
|
N/A | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Recruiting |
NCT03383094 -
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Withdrawn |
NCT03123744 -
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
|
Phase 2 | |
| Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|